{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:17:41Z","timestamp":1787807861018,"version":"build-2784847793"},"reference-count":64,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PANCNGS","award":["PN-III-P1-1.2-PCCDI-2017-0797"],"award-info":[{"award-number":["PN-III-P1-1.2-PCCDI-2017-0797"]}]},{"DOI":"10.13039\/501100007700","name":"Carol Davila University of Medicine and Pharmacy","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007700","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/04fm87419","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis, even in resectable disease. Molecular alterations in the four major driver genes (KRAS, SMAD4, CDKN2A, and TP53) have been associated with disease progression and patient outcomes. However, reliable prognostic biomarkers remain limited, particularly in resected PDAC, where recurrence rates remain high; Case presentation: We report the case of a 71-year-old woman incidentally diagnosed with PDAC carrying KRAS G12R with an ultra-low-variant allele frequency (VAF) SMAD4 mutation, with low baseline neutrophil-to-lymphocyte ratio (NLR) and circulating cell-free DNA (ccfDNA) levels. The patient underwent distal pancreatectomy with splenectomy and portal vein resection with multiple postoperative complications requiring re-intervention. The patient demonstrated excellent tolerance to the therapy, experiencing no significant adverse events and reaching an overall survival of 53 months. Conclusions: This case highlights the potential value of integrating molecular alterations with inflammatory and liquid biopsy biomarkers, including NLR and ccfDNA levels for improving risk stratification in PDAC. A focused review of the literature further supports the need for multimodal prognostic assessment in resected disease.<\/jats:p>","DOI":"10.3390\/reports9030285","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:01:07Z","timestamp":1787670067000},"page":"285","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unexpected Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma Harboring KRAS G12R with an Ultra-Low-VAF SMAD4 Mutation: A Case Report and Mini-Review"],"prefix":"10.3390","volume":"9","author":[{"given":"Bianca","family":"Varzaru","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4216-6570","authenticated-orcid":false,"given":"Adina Emilia","family":"Croitoru","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Medical Oncology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan Andrei","family":"Iacob","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Olimpia","family":"Dima","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Gheorghe","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1038\/s41598-022-08083-6","article-title":"Clinical features and prognostic impact of asymptomatic pancreatic cancer","volume":"12","author":"Takikawa","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Shen, H., Lundy, J., Strickland, A.H., Harris, M., Swan, M., Desmond, C., Jenkins, B.J., and Croagh, D. (2022). KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?. Cells, 11.","DOI":"10.3390\/cells11193175"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/gtmb.2020.0078","article-title":"Clinical Effect of Driver Mutations of KRAS, CDKN2A\/P16, TP53, and SMAD4 in Pancreatic Cancer: A Meta-Analysis","volume":"24","author":"Gu","year":"2020","journal-title":"Genet. Test. Mol. Biomark."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00535-013-0767-4","article-title":"KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer","volume":"48","author":"Boeck","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e173420","DOI":"10.1001\/jamaoncol.2017.3420","article-title":"Association of Alterations in Main Driver Genes with Outcomes of Patients with Resected Pancreatic Ductal Adenocarcinoma","volume":"4","author":"Qian","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1200\/JCO.2002.12.063","article-title":"DPC4\/Smad4 expression and outcome in pancreatic ductal adenocarcinoma","volume":"20","author":"Biankin","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2453588","DOI":"10.1001\/jamanetworkopen.2024.53588","article-title":"KRAS Mutation Status and Treatment Outcomes in Patients with Metastatic Pancreatic Adenocarcinoma","volume":"8","author":"Norton","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"oyag155","DOI":"10.1093\/oncolo\/oyag155","article-title":"KRAS G12R in pancreatic cancer: Why this mutation resists current inhibitor strategies","volume":"31","author":"Kern","year":"2026","journal-title":"Oncologist"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/cts.13029","article-title":"SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma","volume":"14","author":"Fei","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.3390\/cimb46040177","article-title":"Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer","volume":"46","author":"Stefanoudakis","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1111\/cas.14425","article-title":"Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer","volume":"111","author":"Yokose","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccr.2007.01.017","article-title":"KrasG12D and Smad4\/Dpc4 Haploinsufficiency Cooperate to Induce Mucinous Cystic Neoplasms and Invasive Adenocarcinoma of the Pancreas","volume":"11","author":"Izeradjene","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1101\/gad.1478706","article-title":"Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer","volume":"20","author":"Bardeesy","year":"2006","journal-title":"Genes Dev."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Varzaru, B., Iacob, R.A., Bunduc, S., Manea, I., Sorop, A., Spiridon, A., Chelaru, R., Croitoru, A., Topala, M., and Becheanu, G. (2024). Prognostic Value of Circulating Cell-Free DNA Concentration and Neutrophil-to-Lymphocyte Ratio in Patients with Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052854"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.3748\/wjg.v29.i18.2864","article-title":"Endoscopic ultrasound-guided fine-needle aspiration pancreatic adenocarcinoma samples yield adequate DNA for next-generation sequencing: A cohort analysis Stefania","volume":"29","author":"Bunduc","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_18","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/bjc.2013.332","article-title":"Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer","volume":"109","author":"Stotz","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.hpb.2017.12.009","article-title":"A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection","volume":"20","author":"Mowbray","year":"2018","journal-title":"HPB"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1245\/s10434-014-4021-y","article-title":"Blood Neutrophil\u2013Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy","volume":"22","author":"Luo","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Varzaru, B., Iacob, R.A., Croitoru, A.E., Iacob, S.M., Radu, C.E., Dumitrescu, S.M., and Gheorghe, C. (2023). Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma. Cancers Cancers, 15.","DOI":"10.3390\/cancers15133500"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Toledano-Fonseca, M., Cano, M.T., Inga, E., Rodr\u00edguez-Alonso, R., G\u00f3mez-Espa\u00f1a, M.A., Guil-Luna, S., Mena-Osuna, R., de la Haba-Rodr\u00edguez, J.R., Rodr\u00edguez-Ariza, A., and Aranda, E. (2020). Circulating cell-free dna-based liquid biopsy markers for the non-invasive prognosis and monitoring of metastatic pancreatic cancer. Cancers, 12.","DOI":"10.3390\/cancers12071754"},{"key":"ref_24","first-page":"184","article-title":"Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism","volume":"60","author":"Jaiswal","year":"2000","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"BSR20201190","DOI":"10.1042\/BSR20201190","article-title":"Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)","volume":"40","author":"Xiang","year":"2020","journal-title":"Biosci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/fon.09.136","article-title":"Role of systemic inflammatory response in predicting survival in patients with primary operable cancer","volume":"6","author":"Roxburgh","year":"2009","journal-title":"Future Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hirahara, T., Arigami, T., Yanagita, S., Matsushita, D., Uchikado, Y., Kita, Y., Mori, S., Sasaki, K., Omoto, I., and Kurahara, H. (2019). Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5903-y"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/03007995.2017.1408579","article-title":"Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, neutrophil-platelet score and prognostic nutritional index: Do they have prognostic significance in metastatic pancreas cancer?","volume":"34","author":"Dogan","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1038\/ctg.2016.18","article-title":"KRAS G12D Mutation Subtype Is a Prognostic Factor for Advanced Pancreatic Adenocarcinoma","volume":"7","author":"Bournet","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/MPA.0000000000000077","article-title":"KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma","volume":"43","author":"Sinn","year":"2014","journal-title":"Pancreas"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MPA.0b013e31825b6ab0","article-title":"Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival","volume":"42","author":"Shin","year":"2013","journal-title":"Pancreas"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1007\/s11605-008-0577-9","article-title":"Loss of Heterozygosity Predicts Poor Survival After Resection of Pancreatic Adenocarcinoma","volume":"12","author":"Franko","year":"2008","journal-title":"J. Gastrointest. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/1097-0215(20001120)89:6<469::AID-IJC1>3.0.CO;2-L","article-title":"K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma","volume":"89","author":"Kawesha","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.ccell.2024.08.002","article-title":"Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer","volume":"42","author":"McIntyre","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41698-024-00505-0","article-title":"Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma","volume":"8","author":"Yousef","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cho, D., Shin, K., Hong, T.H., Lee, S.H., Kim, Y., Kim, I.-H., Hong, S.-H., Lee, M., and Park, S.J. (2025). Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma with Prognostic and Therapeutic Implications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262210908"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-09-0227","article-title":"SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer","volume":"15","author":"Blackford","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"16704","DOI":"10.18632\/oncotarget.14335","article-title":"Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: A systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Li, Z., Wang, C., Li, J., Wang, X., Li, X., Yu, T., Zhou, J., Wang, X., Zeng, M., and Sun, H. (2024). Identification of SMAD4-mutated pancreatic ductal adenocarcinoma using preoperative contrast-enhanced MRI and clinical characteristics. BMC Med. Imaging, 24.","DOI":"10.1186\/s12880-024-01539-3"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.18632\/oncotarget.14901","article-title":"The DPC4\/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study","volume":"8","author":"Shin","year":"2017","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/0008-5472.CAN-17-3841","article-title":"Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN\/PI3K\u03b3 to Promote Pancreatic Cancer Metastasis","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wang, Z., Li, Y., Zhan, S., Zhang, L., Zhang, S., Tang, Q., Li, M., Tan, Z., Liu, S., and Xing, X. (2019). SMAD4 Y353C promotes the progression of PDAC. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6251-7"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sun, Y., Li, Z., Jian, H., Xia, L., and Lu, S. (2022). Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment. J. Clin. Med., 11.","DOI":"10.3390\/jcm11144003"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Li, B., Zhang, Q., Castaneda, C., and Cook, S. (2024). Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102175"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/0008-5472.CAN-24-2330","article-title":"SMAD4 and KRAS Status Shapes Cancer Cell\u2013Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer","volume":"85","author":"Lloyd","year":"2025","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ccell.2017.09.007","article-title":"A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Article A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer","volume":"32","author":"Mello","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2211937120","DOI":"10.1073\/pnas.2211937120","article-title":"Multifaceted role for p53 in pancreatic cancer suppression","volume":"120","author":"Mello","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.gastro.2022.05.046","article-title":"Arid1a: A Gatekeeper in the Development of Pancreatic Cancer from a Rare Precursor Lesion","volume":"163","author":"Liu","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_49","first-page":"5952","article-title":"Targeting the alterations of ARID1A in pancreatic cancer: Tumorigenesis, prediction of treatment, and prognostic value","volume":"14","author":"Li","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kearns, B., McKell, A., Steveson, I., Worley, P., Barton, B., Bennett, J., Anderson, D., Harris, J., Christensen, J., and Barrott, J.J. (2025). ARID1A and Its Impact Across the Hallmarks of Cancer. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104644"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/0008-5472.CAN-19-3922","article-title":"Loss of ARID1A promotes epithelial-mesenchymal transition and sensitizes pancreatic tumors to proteotoxic stress","volume":"81","author":"Tomihara","year":"2022","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Bannoura, S.F., Khan, H.Y., and Azmi, A.S. (2022). KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1013902"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Sobhani, N., Pittacolo, M., D\u2019angelo, A., and Marchegiani, G. (2025). Recent Anti-KRAS(G12D) Therapies: A \u201cPossible Impossibility\u201d for Pancreatic Ductal Adenocarcinoma. Cancers, 17.","DOI":"10.3390\/cancers17040704"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3390\/curroncol30020130","article-title":"Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy","volume":"30","author":"Falk","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Han, S.-H., Ryu, K.H., and Kwon, A.-Y. (2021). The Prognostic Impact of HER2 Genetic and Protein Expression in Pancreatic Carcinoma-HER2 Protein and Gene in Pancreatic Cancer. Diagnostics, 11.","DOI":"10.3390\/diagnostics11040653"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","article-title":"HER2-targeted therapies in cancer: A systematic review","volume":"12","author":"Zhu","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Xu, L., Xie, Y., Gou, Q., Cai, R., and Bao, R. (2024). HER2-targeted therapies for HER2-positive early-stage breast cancer: Present and future. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1446414"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"21613","DOI":"10.18632\/oncotarget.25085","article-title":"Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: A systematic review","volume":"9","author":"Sheahan","year":"2018","journal-title":"Oncotarget"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ccell.2023.12.002","article-title":"EGFR-activated myofibroblasts promote metastasis of pancreatic cancer ll EGFR-activated myofibroblasts promote metastasis of pancreatic cancer","volume":"42","author":"Mucciolo","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/1078-0432.CCR-25-0821","article-title":"KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We Have All Been Waiting for","volume":"32","author":"Stanger","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/SLA.0000000000000378","article-title":"Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic Cancer","volume":"260","author":"Merkow","year":"2014","journal-title":"Ann. Surg."},{"key":"ref_62","first-page":"1240","article-title":"Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial","volume":"43","author":"Palmer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/apc-25-24","article-title":"ESPAC-4 long-term follow-up: Shall we choose gemcitabine and capecitabine as adjuvant therapy for elderly and low-risk pancreatic adenocarcinoma following surgical resection?","volume":"9","author":"Bertolo","year":"2026","journal-title":"Ann. Pancreat. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Hubner","year":"2019","journal-title":"Eur. J. Cancer"}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/9\/3\/285\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:20:05Z","timestamp":1787804405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/9\/3\/285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":64,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["reports9030285"],"URL":"https:\/\/doi.org\/10.3390\/reports9030285","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}